After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Three off-the-shelf mRNA therapies join intismeran autogene.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Antibody-drug conjugates hitting this target abound.
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
